About: Transgenic milk as a method for the production of recombinant antibodies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Transgenic milk as a method for the production of recombinant antibodies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Transgenic milk as a method for the production of recombinant antibodies
Creator	Birck-Wilson, Eszter Echelard, Yann Kutzko, Joseph Meade, Harry Pollock, Daniel Williams, Jennifer
Source	Elsevier; Medline; PMC
abstract	Abstract Recombinant antibodies and their derivatives are increasingly being used as therapeutic agents. Clinical applications of antibodies often require large amounts of highly purified molecules, sometimes for multiple treatments. The development of very efficient expression systems is essential to the full exploitation of the antibody technology. Production of recombinant protein in the milk of transgenic dairy animals is currently being tested as an alternative to plasma fractionation for the manufacture of a number of blood factors (human antithrombin, human alpha-1-antitrypsin, human serum albumin, factor IX). The ability to routinely yield mg/ml levels of antibodies and the scale-up flexibility make transgenic production an attractive alternative to mammalian cell culture as a source of large quantities of biotherapeutics. The following review examines the potential of transgenic expression for the production of recombinant therapeutic antibodies.
has issue date	1999-12-10(xsd:dateTime)
bibo:doi	10.1016/s0022-1759(99)00151-9
bibo:pmid	10648934
has license	els-covid
sha1sum (hex)	9030725e2b1ee09ed4ac43654b68a998e3fa59b7
schema:url	https://doi.org/10.1016/s0022-1759%2899%2900151-9
resource representing a document's title	Transgenic milk as a method for the production of recombinant antibodies
has PubMed Central identifier	PMC7125573
has PubMed identifier	10648934
schema:publication	Journal of Immunological Methods
resource representing a document's body	covid:9030725e2b1ee09ed4ac43654b68a998e3fa59b7#body_text
is schema:about of	named entity 'TRANSGENIC' named entity 'antithrombin' named entity 'highly' named entity 'transgenic' named entity 'manufacture' named entity 'agents' named entity 'EXPRESSION' named entity 'HUMAN SERUM ALBUMIN' named entity 'ALPHA-1-ANTITRYPSIN' named entity 'MAMMALIAN CELL CULTURE' named entity 'PROTEIN ' named entity 'THERAPEUTIC ANTIBODIES' named entity 'RECOMBINANT ANTIBODIES' named entity 'BLOOD' named entity 'RECOMBINANT PROTEIN' named entity 'REVIEW' named entity 'PLASMA' named entity 'PURIFIED' named entity 'FLEXIBILITY' named entity 'MILK' named entity 'MOLECULES' named entity 'USED' named entity 'TRANSGENIC' named entity 'HIGHLY' named entity 'ESSENTIAL' named entity 'TREATMENTS' named entity 'ATTRACTIVE' named entity 'BIOTHERAPEUTICS' named entity 'LARGE' named entity 'THEIR' named entity 'PRODUCTION' named entity 'METHOD' named entity 'MAKE' named entity 'THERAPEUTIC AGENTS' named entity 'BEING' named entity 'TESTED' named entity 'MULTIPLE' named entity 'RECOMBINANT ANTIBODIES' named entity 'MILK' named entity 'HUMAN' named entity 'APPLICATIONS' named entity 'ANTIBODY' named entity 'YIELD' named entity 'ANTIBODIES' named entity 'SCALE' named entity 'POTENTIAL' named entity 'DAIRY' named entity 'DEVELOPMENT' named entity 'LEVELS' named entity 'RIGHTS' named entity 'TECHNOLOGY' named entity 'EFFICIENT' named entity 'FACTOR' named entity 'RECOMBINANT' named entity 'ANTITHROMBIN' named entity 'AMOUNTS' named entity 'NUMBER OF' named entity 'MANUFACTURE' named entity 'CURRENTLY' named entity 'SCIENCE' named entity 'ANIMALS' named entity 'FRACTIONATION' named entity 'CLINICAL' named entity 'ALTERNATIVE' named entity 'FOLLOWING' named entity 'SOURCE' named entity 'QUANTITIES' named entity 'SYSTEMS' named entity 'PRODUCTION' covid:arg/9030725e2b1ee09ed4ac43654b68a998e3fa59b7 named entity 'All rights reserved' named entity 'antibodies' named entity 'purified' named entity 'transgenic' named entity 'factors' named entity 'large'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software